What is Retatrutide?
The Triple Agonist Explained.

Retatrutide is generating more interest in peptide research than almost any compound in the last decade — and for good reason. Phase III clinical trials reported up to 30% body weight reduction, the highest figure ever recorded for a weight loss compound in a controlled trial. But to understand why that number is so significant, you need to understand what's actually happening at the receptor level.

The Triple Mechanism

Most weight loss compounds work on a single hormonal pathway. Semaglutide, for example, targets GLP-1 receptors — a single mechanism that suppresses appetite and slows gastric emptying. Retatrutide is different. It activates three separate receptor pathways simultaneously: GLP-1, GIP, and glucagon.

Each one does something distinct. GLP-1 receptors control appetite and slow the speed at which food leaves your stomach, meaning you feel full faster and stay full longer. GIP receptors regulate how your body stores fat — when activated, they signal fat cells to reduce storage and improve how the body processes nutrients. Glucagon receptors increase energy expenditure even at rest, essentially raising the metabolic rate independent of activity level.

What the Research Shows

The Phase III TRIUMPH trial data for Retatrutide showed mean body weight reductions of up to 24.2% over 48 weeks at higher doses, with some cohorts reaching 30% in extended follow-up. To put that in context, semaglutide (the active compound in Ozempic/Wegovy) showed approximately 15% weight reduction in comparable trials. Tirzepatide (dual GLP-1/GIP agonist) showed around 22%. Retatrutide's triple mechanism pushes that ceiling significantly higher.

Beyond weight reduction, the research data shows meaningful improvements in metabolic markers including fasting glucose, insulin sensitivity, triglycerides, and blood pressure — consistent with a compound that's working across multiple hormonal pathways rather than a single target.

Once Weekly Administration

One of Retatrutide's practical advantages in research protocols is its half-life. Unlike some peptides that require daily or multiple-weekly injections, Retatrutide is dosed once weekly via subcutaneous injection. This makes it one of the more convenient long-term research protocols available.

A standard research reconstitution uses 2mL of bacteriostatic water with a 10mg vial, producing a 5mg/mL solution. Use our dosing calculator for exact injection volumes based on your target dose.

Purity Matters More Than You Think

With a compound this complex — Retatrutide is a long-chain modified peptide — synthesis quality and purity are critical. Impure or mislabeled batches don't just waste research budget, they produce unreliable results. Our Retatrutide is independently tested by Janoshik, the same lab used by the most trusted suppliers in the Canadian market, and comes back at 99.478% purity. That COA is publicly available on our.